NNNgashi Ngongo

Ngashi Ngongo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ngashi Ngongo has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mpox Clade IIb Virus Introduction into Kinshasa, Democratic Republic of the Congo, July 2025

    by Tony Wawina-Bokalanga, Eddy Kinganda-Lusamaki, Christian Ngandu, Prince Akil-Bandali, Jérémie Kundey-Mafu, Nadege Ngombe, Laurens Liesenborghs, Princesse Paku-Tshambu, Lorenzo Subissi, Pauline-Chloé Muswamba-Kayembe, et al.

    Clade I mpox virus (MPXV) is endemic in the Democratic Republic of the Congo (DRC). Recent studies have described the changing epidemiology of mpox in the country, which has been mainly characterized by the emergence of new MPXV lineages, Clade Ib/sh2023 and Ia/sh2024, associated with sustained human-to-human transmission. Both Clade Ib/sh2023 and Ia/sh2024 are co-circulating in Kinshasa, the capital city of the DRC. Here, we report the first two cases of Clade IIb/sh2017 identified in Kinshasa, DRC, imported from West Africa and locally transmitted. Clinical specimens were collected and tested by PCR. We performed whole genome sequencing using a tiled-amplicon sequencing approach with Clade IIb MPXV-specific primers. The phylogenetic tree shows that Kinshasa Clade IIb MPXV is assigned to Clade IIb/sh2017 within the newly designated lineage G.1, as identified in January 2025 in Sierra-Leone.


  • Open Access

    Mpox Clade IIb Virus Introduction into Kinshasa, Democratic Republic of the Congo, July 2025

    by Tony Wawina-Bokalanga, Eddy Kinganda-Lusamaki, Christian Ngandu, Prince Akil-Bandali, Jérémie Kundey-Mafu, Nadege Ngombe, Laurens Liesenborghs, Princesse Paku-Tshambu, Lorenzo Subissi, Chloé Muswamba-Kayembe, et al.

    Mpox virus lineages associated with sustained human-to-human transmission, Clade Ib/sh2023 and Ia/sh2024, are co-circulating in Kinshasa, Democratic Republic of the Congo (DRC). We report the first two Clade IIb/sh2017 cases identified in DRC, imported from West Africa and locally transmitted, with phylogenetic linkage to the ongoing outbreak in Sierra Leone.

  • Africa leads, multilateral health organisations support

    by Ngashi Ngongo, Tajudeen Raji, Shanelle Hall, Yap Boum


  • Open Access

    Strengthening National Regulatory Authorities in Africa: A Critical Step Towards Enhancing Local Manufacturing of Vaccines and Health Products

    by Alemayehu Duga, Nebiyu Dereje, Mosoka Papa Fallah, Tedi Angasa, Abebe Genetu Bayih, Edinam Agbenu, Ngashi Ngongo, Raji Tajudeen, Jean Kaseya

    The World Health Organization (WHO) Global Benchmarking Tool (GBT) classifies regulatory systems into four maturity levels, with Maturity Level 3 (ML3) signifying a stable and effective regulatory environment. As of January 2025, eight African nations—Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe—have attained ML3 status, marking a significant milestone in the continent’s regulatory landscape. Achieving ML3 confers critical benefits, including reducing substandard and falsified medicines, which enhances public health safety and fosters trust in healthcare systems. This progress encourages local manufacturing, diminishing reliance on imported medicines and promoting economic development. Furthermore, ML3 NRAs are better equipped to address public health emergencies, enabling swift approvals for vaccines and therapeutics while upholding safety standards. Nonetheless, challenges persist, including fragmented regulatory systems, the prevalence of counterfeit medicines, and limited resources. Overcoming these hurdles necessitates enhanced organizational capacity, investments in training, and the promotion of collaboration among NRAs. There is an urgent call for greater political commitment and resource allocation to strengthen regulatory systems across Africa. Achieving and maintaining ML3 status is essential for enhancing medicine regulation, supporting local manufacturing, and improving public health outcomes across the continent. While progress has been made, sustained efforts are crucial to tackling existing challenges and harnessing the full potential of advanced regulatory frameworks.


  • Open Access

    Malaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa

    by Alemayehu Lelisa Duga, Ngashi Ngongo, Mosoka Papa Fallah, Albert Figueras, Carlos Kilowe, Jibril Murtala, Kizito Kayumba, Tedi Angasa, Aminu Kuba, Patrick Chanda Kabwe, et al.